Michael O'Neal, DO
Family Practice · Clearwater, FLNPI 1114088028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 30.6% of the total. Among family practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$834
- Lilly USA, LLC$486
- AstraZeneca$354
- Esperion Therapeutics, Inc.$181
- Amgen$181
- Currax Pharmaceuticals LLC$180
- plus $512 from 16 others
What the payments were for
- Food & beverage$2,49591%
- Education$2329%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $834 |
| Lilly USA, LLC | 24 | $486 |
| AstraZeneca | 21 | $354 |
| Esperion Therapeutics, Inc. | 5 | $181 |
| Amgen | 9 | $181 |
| Currax Pharmaceuticals LLC | 11 | $180 |
| Pfizer | 6 | $102 |
| Idorsia Pharmaceuticals US Inc | 4 | $65 |
| Straumann USA LLC | 1 | $49 |
| Insmed, Inc. | 2 | $44 |
| Bayer | 2 | $42 |
| Boehringer Ingelheim | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Abbott | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Validus Pharmaceuticals LLC | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$118
How this compares
$2,727 in reported general payments places this provider in the 95th percentile of 429 family practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $53,783 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $38,519 |
| FarxigaDapagliflozin Propanediol | 38 | $33,091 |
| EliquisApixaban | 34 | $26,213 |
| RybelsusSemaglutide | 18 | $24,241 |
| Spiriva RespimatTiotropium Bromide | 25 | $23,877 |
| MounjaroTirzepatide | 16 | $16,911 |
| Repatha SureclickEvolocumab | 25 | $14,455 |
| EdarbiAzilsartan Medoxomil | 40 | $10,648 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,007 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,361 |
| JardianceEmpagliflozin | 11 | $6,322 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 16 | $4,256 |
| Rosuvastatin Calcium | 305 | $3,842 |
| Dexlansoprazole DrDexlansoprazole | 14 | $1,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $834 | $78,02464 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Jardiance | $30 | $38,56050 claims |
| AstraZenecaFarxiga | $354 | $33,09138 claims |
| PfizerEliquis, Paxlovid | $102 | $27,64246 claims |
| Lilly USA, LLCMounjaro | $486 | $16,91116 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $11 | $14,90356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 family practice providers in Florida.
Other family practice in Clearwater
- Jennifer MileyPensacola$7K
- Eva LaukhufBradenton$5K
- Hailee BanksHawthorne$5K
- Peach SupupramaiFort Lauderdale$2K
- Jan PavlinecPompano Beach$1K
- Marisol GomezTampa$1K
- Zohaib ZiaTallahassee$711
- Shannon CherayilSpring Hill$447
- Rafael NoguesHialeah$355
- Matthew WelchPanama City Beach$306
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.